Regulatory Status of 18F-FAPI-74 PET in India
18F-FAPI-74 PET is not approved for clinical use in India—it remains an investigational tracer used only in research settings and clinical trials.
Current Regulatory Landscape
The provided evidence contains no guidelines or regulatory documents addressing the approval status of 18F-FAPI-74 PET in India or any other country. The available literature consists entirely of recent research studies (2026) describing exploratory and investigational use of this tracer 1, 2, 3, 4, 5.
Evidence from Research Studies
All available evidence characterizes 18F-FAPI-74 as an investigational agent:
- Clinical trial context: Studies explicitly describe 18F-FAPI-74 imaging as being "conducted as part of a clinical trial" 2
- Exploratory designation: Research is labeled as "prospective, exploratory study" 3 and "pilot study" 1
- No regulatory approval mentioned: None of the studies reference regulatory approval in any jurisdiction, including India
Comparison with Established Tracers
The guidelines provided focus exclusively on approved tracers:
- 18F-FDG: Multiple EANM/SNMMI guidelines establish FDG as the standard PET tracer with defined clinical indications 6, 7, 8, 9
- FAPI tracers mentioned: Guidelines briefly reference FAPI imaging as emerging technology with "retrospective evidence" in breast cancer, but provide no approval status 6
- Regulatory pathway: No FAPI tracer (68Ga or 18F-labeled) has established guideline-level recommendations for routine clinical use
Clinical Implications
For clinical practice in India:
- 18F-FAPI-74 PET cannot be used outside approved research protocols
- Standard imaging with 18F-FDG PET/CT remains the guideline-recommended approach for oncologic indications 7, 9
- Access to 18F-FAPI-74 would require enrollment in institutional review board-approved research studies
Research trajectory: The tracer shows promise in preliminary studies for detecting fibroblast activation in various malignancies 3, 4, 5, but requires larger prospective multicenter validation studies before regulatory consideration 5.
Important Caveats
The absence of India-specific regulatory information in international nuclear medicine guidelines suggests 18F-FAPI-74 has not achieved approval status in major regulatory jurisdictions (FDA, EMA) that typically precede approval in other countries. Any clinical use would constitute off-label experimental therapy requiring appropriate ethical oversight and informed consent.